Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 14Polycystic Ovary Syndrome 12Menorrhagia 7Leiomyoma 7Prostatic Neoplasms 2Osteoporosis 2Neoplasm Metastasis 2Hyperandrogenism 2Vaginitis 1Triple Negative Breast Neoplasms 1Sexual Dysfunction, Physiological 1Neoplasms 1Infertility, Female 1Hot Flashes 1Estrogen Receptor Positive Breast Cancer 1Estrogen Levels Among Breast Cancer Patients 1Coronary Disease 1Cardiovascular Diseases 1Breast Carcinoma In Situ 1Atrophic Vaginitis 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1Abortion, Spontaneous 1

Interventions

pembrolizumab 160Carboplatin 143Paclitaxel 125Cyclophosphamide 93130-nm albumin-bound paclitaxel 66Capecitabine 63Gemcitabine 54Doxorubicin 49Albumin-Bound Paclitaxel 45Taxes 42atezolizumab 40Cisplatin 37Nivolumab 34sacituzumab govitecan 32olaparib 32Epirubicin 32Docetaxel 28eribulin 27Specimen Handling 26Bevacizumab 26durvalumab 25camrelizumab 23Drug Therapy 22Biopsy 22Magnetic Resonance Spectroscopy 21toripalimab 18Radiotherapy 17spartalizumab 16Everolimus 15fludarabine 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Triple Negative Breast Neoplasms × Estradiol × Clear all
NCT03941730 2026-05-12

Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
8 enrolled 9 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡